摘要
目的:通过对医院门诊血管紧张素转换酶(ACE)抑制剂和血管紧张肽(AⅡ)受体阻滞剂的处方调查,以了解医生处方习惯和这两类药物的门诊应用情况。方法:回顾性调查华东医院2001-11～2002-01共3个月的门诊处方,包括ACE抑制剂和AⅡ受体阻滞剂的处方频度、药物类别、剂量、合并处方、患者的性别和年龄分布等情况。结果:3个月门诊处方量分别为18381、22186和20866张,其中ACE抑制剂的处方频度分列为4.2％、5.1％和4.7％,以福辛普利和苯那普利的处方频度最高,依那普利和赖诺普利的处方频度最低。患者平均年龄65.3±10.9岁,男性多于女性,89.9％的患者合并1种或以卜处方药物。AⅡ受体阻滞剂氯沙坦的处方频度分别为0.70％、0.84％和0.88％,患者平均年龄65.1±11.7岁。处方剂量多数在治疗指南和建议推荐的剂量范围的低限。22张处方在用ACE抑制剂的同时合并处方AⅡ受体阻滞剂。结论:门诊ACE抑制剂和AⅡ受体阻滞剂的处方应根据患者的耐受性和经济情况等加以选择,并按治疗指南或建议进行给药方案调整。
OBJECTIVE: To get information about the utilization and prescribing practice of angiotensin converting enzyme (ACE) inhibitors and angiotensin II (A II) receptor blocker in clinic through the prescription review. METHOD: Retrospective survey of clinical prescription of Huadong hospital during Nov, Dec in 2001 and Jan in 2002, including prescribing frequency, drug class, dosage, co-prescribing , and distribution of gender and age of patients. RESULT: Total number of prescription was 18381, 22186 and 20866 respectively in 3 months, the prescribing frequency of ACE inhibitors was 4.2%, 5.1% and 4.7% respectively in 3 months, fosinopril and benazapril were the most common prescribed of the ACE inhibitors while enalapril and lisinopril were the less frequently prescribed. Mean age of patients was 65.3 ± 10.9 years, male more than female, 89.9% of prescriptions included more than one item, the dosage was normal. The prescribing frequency of A II receptor blocker was 0.70%, 0.84% and 0.88% in 3 months, mean age of patients was 65.1 ± 11.7 years. Dosage of many prescriptions were under the dose range of the guideline or instruction. Twenty two of prescriptions were co-prescribed A II receptor blocker. CONCLUSION: We should choose the class of ACE inhibitors and A II receptor blocker rationally according to the tolerance and finances of patients and adjust the regimens following the recommends of guideline or instruction.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2003年第2期151-154,共4页
The Chinese Journal of Clinical Pharmacology
关键词
ACE抑制剂
血管紧张肽Ⅱ受体阻滞剂
门诊
处方
药物利用
angiotensin converting enzyme inhibitor
angiotensin II receptor blocker
prescription
drug utilization
